hrp0095p1-505 | Growth and Syndromes | ESPE2022

The effects of one year of growth hormone treatment on growth and body composition in patients with Temple syndrome

Juriaans Alicia , Trueba-Timmermans Demi , Kerkhof Gerthe , Hokken-Koelega Anita

Background/aims: Temple syndrome (TS14) is a rare imprinting disorder caused by maternal uniparental disomy of chromosome 14 (UPD(14)mat), paternal deletion of 14q32 or by an isolated methylation defect. TS14 is considered a Prader-Willi-like (PWL) disorder. Some patients with TS14 are treated with growth hormone (GH). However, evidence for the effectiveness of GH-treatment in patients with TS14 is very limited.Methods: ...

hrp0092fc14.6 | GH and IGF6 | ESPE2019

Effects of 8 Years of Growth Hormone Treatment on Cognition in Children with Prader-Willi Syndrome

Donze Stephany , Damen Layla , Mahabier Eva , Hokken-Koelega Anita

Context: Children with Prader-Willi syndrome (PWS) generally have mild to moderate cognitive impairment with an IQ between 60 and 70. Growth hormone (GH) treatment is a registered treatment for children with PWS and has been associated with cognitive benefits, attributed to the effects of GH and insulin-like growth factor on brain growth and development. Short-term data suggest positive effects of GH treatment on cognitive functioning in children with PWS. The...

hrp0092t7 | Top 20 Poster | ESPE2019

Establishing of a Novel NGS Tool for the Diagnosis of X-linked Hypophosphatemia (XLH)

Thiele Susanne , Stubbe Anita , Werner Ralf , Hiort Olaf , Hoeppner Wolfgang

X-linked hypophosphatemia (XLH) is the most common genetic disorder of phosphate homeostasis. It is caused by inactivating mutations in the PHEX gene, which encodes a phosphate regulating endopeptidase predominantly expressed in osteoblasts, osteocytes, and odontoblasts.In children there is a broad phenotypic spectrum of XLH ranging from isolated hypophosphatemia without clinical signs up to severe symptoms, such as rickets, extreme lower limb d...

hrp0092p1-36 | Diabetes and Insulin | ESPE2019

Expression of Receptor for Advanced Glycation End-products and its Ligands HMGB1 and s100A12 in Children and Adolescents with New-onset Type 1 Diabetes and in Patients with Longer Disease Duration

Uroic Anita Spehar , Krnic Nevena , Svigir Alen , Putarek Natasa Rojnic

Background: Receptor for advanced glycation end-products (RAGE) is a multiligand receptor up-regulated at sites of inflammation, especially in tissues with accelerated advanced glycation end-products formation. It is additionally stimulated by RAGE ligands S100A12 and HMGB1 released from recruited immune cells thus perpetuating the inflammatory process with a potential role in the development of type 1 diabetes as well as in development in diabetes complicatio...

hrp0089p2-p145 | Fat, Metabolism and Obesity P2 | ESPE2018

The Effect of Exclusive Breastfeeding and Formula Feeding on Body Composition During the First Two Years of Life

de Fluiter Kirsten , Acton Dennis , Hokken-Koelega Anita

Background: Early gain in fat mass (FM) might be influenced by type of feeding. Excessive gain in FM during the first three months of life is associated with an increased risk for adiposity and cardiovascular diseases. This three-month period is also known as the critical window for adiposity programming.Aims: To investigate differences in body composition between exclusively breastfed (BF) and formula fed (FF) infants from birth to 24 months.<p clas...

hrp0089p1-p167 | Growth &amp; Syndromes P1 | ESPE2018

Improved Mental and Motor Development During 3 Years of GH Treatment in Very Young Children with Prader-Willi Syndrome

Donze Stephany , Damen Layla , Mahabier Eva , Hokken-Koelega Anita

Context: Infants and toddlers with Prader-Willi Syndrome (PWS) have a mental and motor developmental delay. Short-term data suggest a positive effect of growth hormone (GH) on mental and motor development in infants and children with PWS. There are, however, no longer-term results about the effects of GH treatment on mental and motor development.Objective: To investigate the longer-term effects of GH on psychomotor development in infants and toddlers wit...

hrp0086rfc14.6 | Growth : Mechanisms | ESPE2016

Effect of Small Size at Birth, Adult Body Size and Growth Hormone Treatment on Telomere Length

Smeets Carolina , Codd Veryan , Samani Nilesh , Hokken-Koelega Anita

Background: Small birth size followed by accelerated weight gain in early life is associated with an increased risk for age-associated diseases, such as cardiovascular disease (CVD) in later life. The underlying causes for this are largely unknown. Leukocyte telomere length (LTL) is a marker of biological age and short LTL is associated with increased CVD-risk. Subjects born small for gestational age (SGA) who remain short are treated with growth hormone (GH) to improve adult ...

hrp0086rfc14.8 | Growth : Mechanisms | ESPE2016

ACAN Mutations in Short Children Born SGA; Growth Response During GH Treatment with Additional GnRHa, and a Proposed Clinical Scoring System

van der Steen Manouk , Hokken-Koelega Anita C.S.

Background: In children born SGA with persistent short stature, growth hormone (GH) treatment is an approved therapy for increasing adult height (AH). Some SGA children have an advanced bone age (BA) during GH. Heterozygous mutations in the ACAN-gene have been described in children with idiopathic short stature and advanced BA.Objective and hypotheses: To assess growth during GH treatment with additional GnRHa treatment, in children with ACAN-gene mutati...

hrp0086p2-p700 | Endocrinology and Multisystemic Diseases P2 | ESPE2016

Effects of 2 Years of Growth Hormone Treatment on Glucose Tolerance in Young Adults with Prader-Willi Syndrome

Donze Stephany , Kuppens Renske , Bakker Nienke , Hokken-Koelega Anita

Background: Growth hormone treatment (GH) in children with PWS results in an improvement in height velocity, body composition and mental and motor development. Discontinuation of GH after attainment of adult height (AH) leads to a decrease in lean body mass and an increase in body fat percentage, which results in an increased risk of impaired glucose tolerance (IGT) and diabetes mellitus type 2 (DM2). Studies in adults with PWS suggest positive effects of GH, but GH is known t...

hrp0082p1-d1-200 | Reproduction | ESPE2014

Testes in Infants with Prader–Willi Syndrome: hCG Treatment, Surgery, and Histology

Bakker Nienke , Wolffenbuttel Katja , Looijenga Leendert , Hokken-Koelega Anita

Background: Boys with PWS often have unilateral or bilateral cryptorchidism. Prospective studies on the treatment of cryptorchidism in boys with PWS are lacking and there is no treatment consensus among pediatricians and urologists.Objective and hypotheses: We hypothesized that hCG treatment would lead to a scrotal position of the testes in infants with PWS and cryptorchidism. We therefore evaluated the effects of hCG treatment on testis position. Additi...